Fisher B J, Perera F E, Cooke A L, Opeitum A, Stitt L
Department of Radiation Oncology, London Regional Cancer Centre, University of Western Ontario, Canada.
Int J Radiat Oncol Biol Phys. 1998 Aug 1;42(1):117-23. doi: 10.1016/s0360-3016(98)00177-1.
To determine the patterns, incidence and risk factors for local-regional recurrence in patients with Stage II and III breast cancer treated with adjuvant tamoxifen alone, without adjuvant radiation.
The records of patients referred to the London Regional Cancer Centre with a diagnosis of breast cancer between 1980-1989 were reviewed. During this time period, it was the policy of the institution to omit local-regional radiation to patients receiving adjuvant systemic therapy. One hundred and fifty axillary node-positive Stage II and III breast cancer patients received adjuvant tamoxifen alone without postoperative local-regional radiation; these patients form the basis of this report.
Median follow-up was 67 months for the entire patient group and 85 months for the living patients. During this time, 42% of patients developed a recurrence, 22% first recurred in local-regional sites. The total incidence of local-regional recurrence (including those patients who first relapsed with systemic metastases) was 30%. Of the segmental mastectomy patients, 13% had recurrences in the intact breast. Of the modified radical mastectomy patients, 10% developed chest wall recurrences. Five percent of recurrences were first in the axilla and 6% in the supraclavicular nodes. Five-year actuarial survival for the entire patient group was 79% and disease-free survival was 60%, with a median disease-free survival time of 87 months. Five-year local-regional relapse-free survival was 76%. Five-year local-regional relapse-free survival was < 76% for those patients with 4 or more positive axillary nodes, regardless of tumor size. On univariable analysis, positive resection margins, number of positive axillary nodes, menopausal status, and negative estrogen and progesterone receptors were significant for isolated local-regional recurrence. On multivariable analysis, only positive resection margins and negative receptors remained significant. In terms of regional recurrence specifically, negative estrogen and progesterone-receptor status and positive resection margins were, again, prognostically significant.
Postmenopausal women receiving adjuvant tamoxifen who have positive resection margins, > or = 4 positive axillary nodes and/or negative estrogen and progesterone receptors, are at higher risk of local and regional recurrence and should, therefore, receive local-regional radiation.
确定仅接受辅助性他莫昔芬治疗且未接受辅助性放疗的II期和III期乳腺癌患者局部区域复发的模式、发生率及危险因素。
回顾了1980年至1989年间转诊至伦敦地区癌症中心且诊断为乳腺癌的患者记录。在此期间,该机构的政策是不对接受辅助性全身治疗的患者进行局部区域放疗。150例腋窝淋巴结阳性的II期和III期乳腺癌患者仅接受辅助性他莫昔芬治疗,未进行术后局部区域放疗;这些患者构成了本报告的基础。
整个患者组的中位随访时间为67个月,存活患者为85个月。在此期间,42%的患者出现复发,22%的患者首次复发于局部区域部位。局部区域复发的总发生率(包括那些首先出现全身转移复发的患者)为30%。在接受区段乳房切除术的患者中,13%在完整乳房出现复发。在接受改良根治性乳房切除术的患者中,10%出现胸壁复发。5%的复发首先出现在腋窝,6%出现在锁骨上淋巴结。整个患者组的5年精算生存率为79%,无病生存率为60%,无病生存时间中位数为87个月。5年局部区域无复发生存率为76%。对于腋窝淋巴结阳性4个或更多的患者,无论肿瘤大小,其5年局部区域无复发生存率均<76%。单因素分析显示,切缘阳性、腋窝淋巴结阳性数目、绝经状态以及雌激素和孕激素受体阴性对于孤立性局部区域复发具有显著意义。多因素分析显示,只有切缘阳性和受体阴性仍然具有显著意义。就区域复发而言,雌激素和孕激素受体阴性状态以及切缘阳性在预后方面再次具有显著意义。
接受辅助性他莫昔芬治疗的绝经后女性,若切缘阳性、腋窝淋巴结阳性≥4个和/或雌激素及孕激素受体阴性,则局部和区域复发风险较高,因此应接受局部区域放疗。